Skip to main content

Advertisement

SpringerLink
Log in

Molecular Mechanisms of the Actions of Brain Peptide-Containing Drugs: Cortexin

  • Published:
Neuroscience and Behavioral Physiology Aims and scope Submit manuscript

This article considers new data on the key molecular mechanisms which may underlie the neuroprotective properties of multicomponent organ-specific medicinal formulations consisting of peptide hydrolysates extracted from animal brains. Such formulations, including cortexin, are currently quite widely used in the treatment of cerebral pathologies. The potential molecular mechanisms of the neuroprotective effects of cortexin are shown to be diverse and to influence key processes underlying neuroplasticity: signal transduction, energy metabolism, proteolytic modification of proteins, brain cell structures, and neuroinflammation processes. The pleiotropic nature of the mechanisms of action of cortexin results from the composition of the formulation, which contains a multitude of different neuropeptides. The tissue specificity of the molecular mechanisms identified here to a significant extent determines the efficacy of the agent in cerebral pathologies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. K. A. Witt, T. J. Gillespie, J. D. Huber, et al., “Peptide drug modifications to enhance bioavailability and blood–brain barrier permeability,” Peptides, 22, No. 12, 2329–2343 (2001), https://doi.org/https://doi.org/10.1016/s0196-9781(01)00537-x.

  2. L. Malavolta and F. R. Cabral, “Peptides: important tools for the treatment of central nervous system disorders,” Neuropeptides, 45, No. 5, 309–316 (2011), https://doi.org/https://doi.org/10.1016/j.npep.2011.03.001.

  3. I. Gozes, “Neuroprotective peptide drug delivery and development: potential new therapeutics,” Trends Neurosci., 24, No. 12, 700–705 (2001), https://doi.org/https://doi.org/10.1016/s0166-2236(00)01931-7.

  4. N. V. Gulyaeva, “Molecular mechanisms of neuroplasticity: an expanding universe,” Biochemistry, 82, No. 3, 237–242 (2017), https://doi.org/https://doi.org/10.1134/S0006297917030014.

  5. I. P. Ashmarin, “Potentials for the practical application and some basic studies of small regulatory peptides,” Vopr. Med. Khim., 30, No. 3, 2–7 (1984).

    CAS  PubMed  Google Scholar 

  6. I. P. Ashmarin, S. A. Chepurnov, and A. P. Kulaichev, “Cascade unidirectional regulatory processes of short-lived peptides,” Fiziol. Zh,, 75, No. 5, 627–632 (1989).

    CAS  Google Scholar 

  7. S. V. Koroleva and I. P. Ashmarin, “A functional continuum of regulatory anxiety-enhancing peptides. The search for complexes providing the optimal basis for developing inhibitory therapeutic agents,” Neurosci. Behav. Physiol., 36, No. 2, 157–162 (2006).

    Article  CAS  Google Scholar 

  8. O. A. Gomazkov, “Cortexin: molecular mechanisms and targets for neuroprotective activity,” Zh. Nevrol. Psikhiat., 115, No. 8, 99–104 (2015).

    Article  CAS  Google Scholar 

  9. M. Brainin, “Cerebrolysin: a multi-target drug for recovery after stroke,” Expert Rev. Neurother., 18, 1–7 (2018), https://doi.org/https://doi.org/10.1080/14737175.2018.1500459.

  10. M. Yu. Stepanichev, M. V. Onufriev, D. I. Peregud, et al., “Effects of cortexin on free-radical oxidation and inflammatory processes in rats with normal and accelerated aging,” Neirokhimiya, 35, No. 2, 187–198 (2018), https://doi.org/https://doi.org/10.7868/S1027813318020127.

  11. V. A. Aniol, Yu. A. Novitskaya, T. N. Borodina, et al., “Assessment of the antiepileptic effects of cortexin in a model of convulsive activity,” Zh. Nevrol. Psikhiat., 111, No. 12, 68–73 (2011).

    CAS  Google Scholar 

  12. N. V. Gulyaeva, “Staging of changes in neuroplasticity in epileptogenesis using temporal epilepsy as an example,” Zh. Nevrol. Psikhiat. (spec. iss.), 117, No. 9, 10–16 (2017), https://doi.org/https://doi.org/10.17116/jnevro20171179210-16.

  13. A. A. Yakovlev and N. V. Gulyaeva, “The pleiotropic functions of brain proteinases: methodological approaches to studies and the search for the substrates of caspases,” Biokhimiya, 76, No. 10, 1079–1086 (2011), https://doi.org/https://doi.org/10.1134/S0006297911100014.

  14. A. A. Yakovlev and N. V. Gulyaeva, “Possible role of proteases in preconditioning of brain cells to pathological conditions,” Biochemistry, 80, No. 2, 163–171 (2015), https://doi.org/https://doi.org/10.1134/S00062979.15020030.

  15. A. A. Yakovlev, A. A. Lyzhin, L. G. Khaspekov, et al., “Peptide drug cortexin inhibits brain caspase-8,” Biomed. Khim., 63, No. 1, 27–31 (2017), https://doi.org/https://doi.org/10.18097/PBMC2017630127.

Download references

Author information

Authors and Affiliations

  1. Institute of Higher Nervous Activity and Neurophysiology, Russian Academy of Sciences, Moscow, Russia

    N. V. Gulyaeva

  2. Solov’ev Scientific and Applied Psychoneurology Center, Moscow Health Department, Moscow, Russia

    N. V. Gulyaeva

Authors
  1. N. V. Gulyaeva
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to N. V. Gulyaeva.

Additional information

Translated from Zhurnal Nevrologii i Psikhiatrii imeni S. S. Korsakova, Vol. 118, No. 10, Iss. 1, pp. 93–96, October, 2018.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gulyaeva, N.V. Molecular Mechanisms of the Actions of Brain Peptide-Containing Drugs: Cortexin. Neurosci Behav Physi 49, 1067–1070 (2019). https://doi.org/10.1007/s11055-019-00839-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11055-019-00839-4

Keywords

Search

Navigation